Why Ionis Pharmaceuticals, Inc. (IONS) stock moved
Updated Sep 28, 2026
Ionis Pharmaceuticals, Inc. (IONS) shares rose 1.6% to $44.50 as of September 28, 2026, a modest gain from the prior close of $43.81. BestStocks flagged the session as a major change for IONS. Below, we break down what changed for IONS, why it matters for investors, how the stock reacted, and the catalysts on the calendar.
What happened
IONS climbed 1.6% to $44.50
IONS rose 1.6% in its latest session, moving from $43.81 to $44.50.
ValuationLow confidence
Rel. volume
2.0×
Above Avg
Vs peers
—
No comparable peers
Market cap
$7.4B
NASDAQ Global Select
Analyst target
$84
+88.9% vs price
Price chart
Sep 28
Not enough price data.
E earnings
F filing
A analyst
V/N other
click a marker to highlight
Change events — click to jump to details
What it means for Ionis Pharmaceuticals, Inc. investors
For Ionis Pharmaceuticals, Inc. investors, the recent signals are mixed, leaving the near-term picture neutral / mixed. On the constructive side: Material positive event; Positive 1.6% session move. Weighing against that: Ionis Pharmaceuticals shares fell 4.10% to $44.84, pressured by a confluence of sector headwinds and company-specific concerns; Ionis Pharmaceuticals fell 3.95% to $55.79 intraday following the announcement that its Phase 3 pelacarsen cardiovascular outcome study (conducted with partner Novartis) missed its primary endpoint, per web sources. Wall Street's consensus price target sits at $84.08, implying +88.9% upside from $44.50. Over the past 90 days analysts logged 0 upgrades and 2 downgrades. BestStocks rates the overall signal quality low (49/100). With earnings roughly 37 days out, the next report is the most likely near-term test of the move.
IONS price reaction
IONS last traded at $44.50, up $0.69 (+1.57%) from the previous close of $43.81. The session traded on 2.0× average volume (above avg), so the move carried above-average conviction.
Bullish and bearish analyst opinions on Ionis Pharmaceuticals, Inc. (IONS)
The consensus analyst price target on Ionis Pharmaceuticals, Inc. (IONS) is $84.08, 88.9% above the recent $44.50. Over the past 90 days analysts logged 0 upgrades, 25 maintains, and 2 downgrades. Here is how the bullish and bearish cases on IONS line up.
▲ The bullish case
+Wall Street's consensus price target of $84.08 implies +88.9% upside from $44.50.
+The Street's most bullish target is $115.00 (+158.4%).
+Material positive event.
+Positive 1.6% session move.
+Positive price momentum.
▼ The bearish case
−2 analyst downgrades in the past 90 days, most recently BMO Capital to Market Perform (2026-08-19).
−Ionis Pharmaceuticals shares fell 4.10% to $44.84, pressured by a confluence of sector headwinds and company-specific concerns.
−Ionis beat Q2 earnings and sales estimates on July 30 and reaffirmed its 2026 outlook (Zacks), but the stock fell 3.22% to $51.57 intraday, coinciding with a Pomerantz Law Firm investigation announcement on the same date (PRNewswire).
Bull vs bear balanceNeutral / Mixed
BearishNeutralBullish
Weighing both sides, BestStocks' composite read of recent signals is roughly balanced, as the bull-versus-bear meter above shows. This is an educational summary of the bull and bear case, not investment advice.
Analyst price targets and ratings are FMP consensus figures as of Sep 28, 2026; other aggregators may differ. High and low targets show the range of estimates, not forecasts.
Ionis Pharmaceuticals shares fell 4.10% to $44.84, pressured by a confluence of sector headwinds and company-specific concerns. Broad healthcare weakness (XLV down over 1%) driven by rising Treasury yields, oil prices above $90/barrel, and U.S.-Iran geopolitical tensions weighed on the biotech sector. Overlaid on that backdrop, lingering investor caution about Ionis's July Phase 3 trial failure for eplontersen and scrutiny over a $546 million equity shelf offering tied to an ESOP further dampened sentiment ahead of the Zilganersen PDUFA decision.
Ionis Pharmaceuticals fell 2.04% to $46.28 following a Phase 3 clinical trial miss for pelacarsen (partnered with Novartis), which failed to meet its primary cardiovascular endpoint, according to reports cited by finance.yahoo.com and marketwatch.com. The decline extends a multi-day selloff triggered by this setback and compounded by July's earlier eplontersen trial failure; volume of 3.0M shares runs 1.55x normal for this point in the session.
Ionis Pharmaceuticals fell 6.75% to $47.97, extending losses driven by recent Phase 3 trial disappointment for pelacarsen (partnered with Novartis) that missed its primary endpoint, compounded by analyst price target cuts from firms including Guggenheim (down to $80) and Barclays following pipeline setbacks earlier in the summer. Volume ran 1.65x normal for this point in the session, reflecting elevated trading activity amid the negative catalyst.
Material / Earnings2026-09-14
Ionis Pharmaceuticals, Inc. (IONS) moved −6.51% from $55.02 to $51.44 on 2026-09-14, reaching a new 30-day low on modestly elevated volume (1.4x the 5-day average). The decline occurred amid sector-wide pressure following Novartis's Phase 3 clinical trial failures for rival RNA-targeted cardiovascular and rare-disease therapies (del-desiran and pelacarsen), which sparked contagion selling across biotech peers including IONS.
Material / Earnings2026-09-08
Ionis Pharmaceuticals (IONS) moved +8.74% from $52.15 to $56.71 on 2026-09-08, reversing earlier losses after the Phase 3 pelacarsen trial with partner Novartis failed to meet its primary endpoint on September 4. Volume was 3.6x the 5-day average.
Ionis Pharmaceuticals fell 3.95% to $55.79 intraday following the announcement that its Phase 3 pelacarsen cardiovascular outcome study (conducted with partner Novartis) missed its primary endpoint, per web sources. The stock has declined over 10% since the initial announcement on September 4, 2026, with elevated volume of 7.96x the time-adjusted average reflecting heightened selling pressure.
Ionis Pharmaceuticals fell 6.08% to $57.60 as investors reacted to a newly filed investor investigation by Pomerantz LLP and downgraded EPS forecasts from HC Wainwright, which projected higher quarterly losses through 2026 and 2027. The decline extends pressure from earlier setbacks including disappointing Phase 3 data for eplontersen and competition concerns. Volume of 2.55M shares traded at 1.30x the historical average for this point in the session.
Ionis Pharmaceuticals rose 2.97% to $63.88, driven by institutional buying and positive analyst sentiment ahead of the European Society of Cardiology (ESC) Congress. Canaccord reiterated a Buy rating with a $95 price target, BMO Capital Markets upgraded to Hold, and Piper Sandler reaffirmed Buy; firms including Connor Clark & Lunn Investment Management and Algert Global LLC initiated or expanded positions in the last 24–48 hours. Volume stood at 852,477 shares (120 min into session), tracking 1.13x normal for this time.
In-depth IONS event analyses
Permanent, dated analyses of IONS's most significant sessions.
Why did Ionis Pharmaceuticals, Inc. (IONS) stock move?
IONS rose 1.6% to $44.50. No single company-specific catalyst was confirmed during the move window, and it looks technical.
How much did IONS stock rise?
IONS gained 1.57% ($0.69) versus the prior close of $43.81, last trading at $44.50 on 2.0× average volume.
When is Ionis Pharmaceuticals, Inc.'s next earnings date?
IONS's next earnings report is estimated for 2026-11-04 — about 37 days away.
What is the analyst price target for IONS?
The consensus analyst price target for IONS is $84.08, about 88.9% above the current $44.50. Over the past 90 days, analysts recorded 0 upgrades, 25 maintains, and 2 downgrades.
How BestStocks tracks IONS
This page is generated automatically by BestStocks' change-detection system after its price and volume cleared IONS-specific materiality thresholds, triggering an evidence check. It draws on 20 tracked change events for IONS, cross-checked against the data sources listed below. Price, volume, and market-capitalization figures are the live intraday quote as of September 28, 2026 and refresh as new information is detected; for companies with multiple share classes, market-cap figures can differ by data source. Analyst price targets and ratings are FMP consensus. This is an educational summary of what changed and why — not personalized investment advice.
